A Phase 2a clinical trial study the efficacy of psilocybin-assisted therapeutic protocols in patients suffering from Anorexia Nervosa
Latest Information Update: 26 Sep 2022
Price :
$35 *
At a glance
- Drugs Psilocybin (Primary)
- Indications Anorexia nervosa
- Focus Therapeutic Use
- 22 Sep 2022 Status changed from planning to not yet recruiting, according to a Xpira Pharmaceuticals media release.
- 22 Sep 2022 According to a Xpira Pharmaceuticals media release, the company has obtained approval from the United States Food and Drug Administration (FDA) for its first Investigational New Drug (IND) application.
- 21 Sep 2022 New trial record